SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: conix, Phaeton, $Pistol Pete$
Search This Board:
Last Post: 7/27/2016 11:01:21 AM - Followers: 355 - Board type: Free - Posts Today: 4


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Statement of Changes in Beneficial Ownership (4) 07/18/2016 06:31:00 PM
MNKD News: MannKind Corporation to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference 07/08/2016 05:00:00 PM
MNKD News: Biotechnology Equities at a Glance -- MannKind, bluebird bio, OncoGenex Pharma, and Hevat Biologics 06/27/2016 08:25:00 AM
MNKD News: MannKind Announces Late-Breaking Data Reinforcing Faster Onset and Shorter Duration of Action Compared to Mealtime Insulins 06/12/2016 03:00:00 PM
MNKD News: MannKind Announces Collaboration with JDRF 06/10/2016 09:00:00 AM
#19138  Sticky Note One of the other uses for Technosphere use Phaeton 07/09/16 03:31:47 PM
#16574  Sticky Note $MNKD ~ MannKind Corp. due diligence report $Pistol Pete$ 12/18/15 01:14:52 AM
#19369   $MNKD Daily Chart $Pistol Pete$ 07/27/16 11:18:42 AM
#19368   MannKind Corp.’s (NASDAQ: MNKD) short interest, at around conix 07/27/16 11:01:21 AM
#19367   MNKD remains on a RSI(10) buy since JULY TREND1 07/27/16 10:45:14 AM
#19366   $MNKD Daily & Weekly Chart http://stock $Pistol Pete$ 07/27/16 01:18:56 AM
#19365   As of 7/15 short interest up slightly to tyfoidhana 07/26/16 08:24:30 PM
#19364   By Sep 2016 we should see some good TREND1 07/26/16 06:10:39 PM
#19363   Agree. Hoping for 3,000 scripts per week by TREND1 07/26/16 06:08:39 PM
#19362   Is there any one who thinks MNKD can exwannabe 07/26/16 06:04:31 PM
#19361   I think the coming dilution will be a TREND1 07/26/16 05:59:08 PM
#19360   Is there any one who thinks MNKD can TREND1 07/26/16 05:47:50 PM
#19359   cajcad Comments (14) /+ Follow /Send Message TREND1 07/26/16 01:26:38 PM
#19358   That's very sweet of you to say that Denise Chanterelle 07/26/16 11:14:28 AM
#19357   Thank you, persistence, vision, kind, caring, intelligent mind WHS 07/26/16 03:42:56 AM
#19356   Words of wisdom Hypi, and the best way Denise Chanterelle 07/26/16 01:44:56 AM
#19355   Zanias So what is the reason MNKD is TREND1 07/25/16 11:32:31 PM
#19354   An arificial pancreas is going to be expensive. Zanias 07/25/16 11:06:29 PM
#19353   No it won't !!! Brentpdc 07/25/16 09:48:24 PM
#19351   ***** Artificial pancreas will replace AFREEZA and save lives. TREND1 07/25/16 09:29:12 PM
#19349   MORE COMPETION FOR AFREZZA TREND1 07/25/16 02:56:33 PM
#19348   ***** 6/30/16 As promised, Medtronic $MDT) has filed TREND1 07/25/16 02:00:07 PM
#19347   We know that a blood cell lives 90 days. TREND1 07/25/16 11:29:38 AM
#19346   Interesting blood level chart, but I have some questions. exwannabe 07/25/16 11:05:57 AM
#19345   ***** MNKD DAY TREND1 07/25/16 10:37:03 AM
#19344   *****The top line is a patient experiencing the TREND1 07/25/16 10:31:59 AM
#19343   ***** Mannkind - Did Afrezza Prescriptions Just Bottom Out? TREND1 07/25/16 10:22:52 AM
#19342   Low volume to me in a stock as tyfoidhana 07/24/16 10:40:50 PM
#19341   Who mike that? WHS 07/24/16 10:28:16 PM
#19340   Friday low volume was interesting as I really Hypi 07/24/16 09:51:27 PM
#19339   ***** A must read . IMHO. TREND1 07/24/16 04:42:48 PM
#19338   I left out MNKD. God, I lost pphm_mike 07/24/16 04:30:15 PM
#19337   ***** MNKD MONTHLY 3 LINE BREAK CHART TREND1 07/24/16 02:37:18 PM
#19336   And to test that BG, dessert should be Denise Chanterelle 07/24/16 11:46:17 AM
#19335   will the new boxes make you a user SidVicious 07/24/16 11:43:12 AM
#19334   It seems if you want to sell a tyfoidhana 07/24/16 11:34:11 AM
#19333   That's right Hypi. And, I'd also like to Denise Chanterelle 07/24/16 11:24:58 AM
#19332   And then, there's this... Denise Chanterelle 07/24/16 10:50:19 AM
#19331   Here's a better view of the new Denise Chanterelle 07/24/16 10:47:39 AM
#19330   These investor conferences are typically worthless and even SidVicious 07/24/16 10:06:52 AM
#19329   Good post from another board on Mike C's Hypi 07/24/16 09:28:20 AM
#19328   Total scripts tend is down. WHS 07/24/16 07:06:47 AM
#19327   All good as MNKD and Afrezza 2.0 starts Hypi 07/23/16 08:32:26 PM
#19326   Pictures of the new Afrezza boxes; 5 pictures, Denise Chanterelle 07/23/16 05:03:19 PM
#19325   MNKD's big mistake was it started to sell AFREEZA. TREND1 07/23/16 02:16:33 PM
#19324   At this stage, it is my estimation that TREND1 07/23/16 02:00:22 PM
#19323   Total scripts tend is down. TREND1 07/23/16 11:41:08 AM
#19322   Posters, fudsters etc have no effect on the SidVicious 07/22/16 05:11:35 PM
#19320   I do believe today qualified for the lowest tyfoidhana 07/22/16 04:40:23 PM
#19319   ***** This past week's Afrezza sales came in TREND1 07/22/16 03:01:58 PM
#19318   ***** MannKind - Afrezza Sales Pacing Below My TREND1 07/22/16 02:11:46 PM
#19317   Like I've been saying its a Q4 story Hypi 07/22/16 11:34:12 AM